Breast cancer - locally advanced HER2 positive breast cancer
The PBS subsidises trastuzumab for patients with human epidermal growth factor receptor 2 (HER2) positive locally advanced breast cancer.
Treatment with trastuzumab can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, Section 85 and Section 100—for the Efficient Funding of Chemotherapy, for a patient with HER2 positive locally advanced breast cancer.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing trastuzumab.
From 1 July 2018, you can call the PBS Complex Drugs Programs enquiry line to make initial authority applications for early HER2 positive breast cancer.
Make all initial applications for authority approval to prescribe trastuzumab for the treatment of HER2 positive locally advanced breast cancer in writing and:
- upload through Health Professional Online Services (HPOS), or
- post to the PBS Complex Drugs Programs
All applications must include the completed:
- authority prescription form(s)
- locally advanced HER2 positive breast cancer Initial PBS authority application supporting information form
- relevant attachments
The prescription must clearly state if the IV or SC route of administration is requested.
To make continuing applications for treatment with trastuzumab call the PBS Complex Drugs Programs enquiry line.
Call the PBS Complex Drugs Programs enquiry line for more information.
Page last updated: 22 February 2019